Does your child have Angelman syndrome?
If your child has Angelman syndrome consider participating in the NEPTUNE study.
NEPTUNE is a pediatric clinical study that is evaluating the investigational
medicine gaboxadol (OV101) to determine if it improves symptoms associated with Angelman syndrome, such as the ability to sleep, use of gross and fine motor skills, behavior and communication.
Study participation should last approximately
4 to 5 months.
To be eligible, your child must meet these initial criteria:
Be between the ages of 4 and 12*
Have a confirmed diagnosis of Angelman syndrome
Have fewer than 3 seizures lasting less than 3 minutes weekly
Take the prescreener to find out if your child may qualify to participate in NEPTUNE.
*Study enrollment will start with ages 9-12 and then enroll ages 4-8.
